Back

Medicare’s RAPID Pathway Changes the U.S. Playbook for Breakthrough Devices

If you lead a medtech company in Europe or Asia and your device carries FDA Breakthrough designation, you probably have a U.S. plan that starts with the FDA submission and treats Medicare as a second project for later. In 2026 that sequence stopped working. Medicare now wants to be in the room before your pivotal study starts, and the payment shortcut many breakthrough devices relied on is closing. The decision in front of you is when to bring CMS into your evidence plan, and the honest answer for most companies is earlier than they think.

The short answer

CMS and FDA have proposed RAPID (Regulatory Alignment for Predictable and Immediate Device), a pathway that would let eligible Breakthrough Devices receive a proposed Medicare national coverage determination on the same day FDA authorizes them, with a final decision targeted 60 days later for Class II devices and 90 days later for Class III. To qualify, a company must enter at the IDE pre-submission stage and run a U.S. study that enrolls Medicare beneficiaries and measures outcomes both agencies agree on. At the same time, CMS has finalized the end of the “alternative pathway” that exempted Breakthrough Devices from proving substantial clinical improvement for new technology add-on payments, with a transition only for devices designated by September 30, 2026. As of November 2026, RAPID is still a proposal: comments closed on October 13, 2026, and the pathway takes effect when CMS publishes its final notice.

What CMS and FDA announced in 2026

On April 23, 2026, CMS and FDA jointly announced the RAPID coverage pathway. The idea is simple to describe. Today, a device can be authorized by FDA and then wait about a year or more for national Medicare coverage, by CMS’s own estimate. RAPID aligns the two agencies on evidence before the pivotal study, so the data that supports FDA review can also support a coverage decision. CMS says this could make national coverage and payment possible as soon as two months after market authorization.

Time to national Medicare coverage

From FDA authorization to a final coverage decision

Current routeCMS estimate
About 12 months or more
RAPID, Class IIProposed target
60 days
RAPID, Class IIIProposed target
90 days
03 mo6 mo9 mo12 mo15 mo

Dashed segment: CMS says “approximately a year or more” today. RAPID targets are from the August 2026 proposed notice and are not yet in effect. Sources: CMS, April 23, 2026; Cooley, October 8, 2026.

The formal proposal followed in August. CMS published a proposed procedural notice in the Federal Register (91 Fed. Reg. 51710, August 11, 2026) and accepted comments until October 13, 2026. According to Cooley’s summary of the notice and King & Spalding’s analysis, the proposal works in four stages.

How RAPID would work

Four stages, two agencies at the same table

01
Before the study

IDE pre-submission

Kick-off with FDA and CMS. FDA screens eligibility and reviews the protocol; CMS checks the Medicare benefit category and the planned outcomes.

02
Protocol

Formal IDE

The protocol goes to FDA, then CMS. CMS confirms it intends to issue a proposed coverage decision.

03
Day of authorization

Proposed NCD

The study is completed and filed. CMS posts a proposed national coverage determination the day FDA authorizes the device; a 30-day comment period opens.

04
60 to 90 days later

Final NCD

CMS targets a final decision 60 days after authorization for Class II devices and 90 days for Class III.

Proposed process, not yet final. Sources: Cooley; King & Spalding.

Eligibility is narrow by design. The proposal covers presumptive Class II Breakthrough Devices that participate in FDA’s Total Product Life Cycle Advisory Program (TAP) and plan a De Novo request, and Class III Breakthrough Devices that plan a PMA, whether or not they are in TAP. In vitro diagnostics are excluded. Devices that fall outside a Medicare benefit category, are already governed by an NCD, or are not separately payable are also out. Where evidence gaps remain, CMS may issue coverage under Coverage with Evidence Development, which can limit coverage to patients enrolled in a CMS-defined study.

Eligibility at a glance

Who the RAPID proposal covers

In scope

  • Class II Breakthrough Devices in FDA’s TAP program, planning a De Novo request
  • Class III Breakthrough Devices planning a PMA, in TAP or not
  • Entry at the IDE pre-submission stage
  • A pivotal study that enrolls Medicare beneficiaries and measures outcomes both agencies agree on

Out of scope

  • In vitro diagnostics
  • Devices outside a Medicare benefit category or not separately payable
  • Devices already governed by a national coverage determination
  • Devices already past IDE pre-submission (open question in the proposal)

Based on the August 11, 2026 proposed notice as summarized by Cooley and King & Spalding.

One more change matters for anyone already planning around the older route. CMS said in April that the Transitional Coverage for Emerging Technologies (TCET) pathway would be paused for new candidates while it implements RAPID. The standard NCD process remains available.

The payment shortcut that is closing

Coverage says Medicare will pay for a device. Payment levels decide whether a hospital can afford to use it. For years, Breakthrough Devices had an advantage here: an “alternative pathway” to new technology add-on payments (NTAP) for inpatient care, and to transitional pass-through payments for outpatient care, that exempted them from showing substantial clinical improvement over existing options.

In the FY 2027 inpatient payment final rule, issued July 31, 2026, CMS repealed that alternative pathway beginning with FY 2028 applications, according to Applied Policy and Gardner Law. CMS did include a transition. A technology that held Breakthrough designation by September 30, 2026, and receives FDA marketing authorization for that indication by May 1, 2028, can still use the alternative NTAP pathway through FY 2029. A parallel exception keeps the outpatient pass-through alternative pathway available through CY 2029 for devices designated by the same date. Technologies already approved for these payments keep them for their normal duration.

September 30, 2026 has now passed. If your device was not designated by then, plan on proving substantial clinical improvement like any other new technology, with the evidence budget that implies. Read the CMS new technology page for the current application cycle before you commit to a timeline.

Key dates

RAPID and the NTAP change on one timeline

HappenedWhere things standAhead
  1. Apr 23, 2026CMS and FDA announce RAPID. TCET paused for new candidates.
  2. Jul 31, 2026FY 2027 inpatient final rule repeals the NTAP alternative pathway from FY 2028 applications.
  3. Aug 11, 2026RAPID proposed notice published (91 Fed. Reg. 51710).
  4. Sep 30, 2026Breakthrough designation cut-off for the NTAP and pass-through transition.
  5. Oct 13, 2026RAPID comment period closes.
  6. Nov 2026Final RAPID notice pending. The pathway takes effect when it is published.Date not set
  7. May 1, 2028Latest FDA authorization date for designated devices to keep the alternative NTAP pathway.
  8. FY / CY 2029Transition ends for the alternative NTAP (FY 2029) and outpatient pass-through (CY 2029) pathways.

Sources: CMS; Applied Policy; Gardner Law; Cooley.

Why this hits companies outside the U.S. harder

Many international medtech companies follow a familiar sequence. They generate clinical data at home, win a CE mark or a domestic approval, build a reference base of hospitals, and only then open the U.S. file. That sequence was workable when Medicare coverage was a separate, later conversation. RAPID changes the arithmetic in three practical ways.

First, the study population. RAPID requires an IDE study that enrolls Medicare beneficiaries. CMS has said it finds it hard to make a “reasonable and necessary” decision when pivotal studies underrepresent Medicare patients. A trial run entirely in European or Asian hospitals, however strong, does not meet that requirement on its own. You will need U.S. sites and a recruitment plan that reaches Medicare patients.

Second, timing. Entry happens at the IDE pre-submission stage. If you are already past that point and enrolling under an approved IDE, the proposal as written does not cover you, although CMS asked for comments on a temporary process for devices in that position. Watch the final notice for how that question was answered.

Third, endpoints. FDA asks whether a device is safe and effective. CMS asks whether it improves health outcomes for Medicare beneficiaries. Under RAPID those two questions are designed into one protocol from the start, so the outcomes you choose need to make sense to a payer as well as a regulator.

From the operator’s side of U.S. healthcare, the lesson is consistent. Authorization opens the door to the market, and payment decides how many patients actually walk through it. RAPID is CMS telling manufacturers to design for both from day one.

A decision framework for your U.S. evidence plan

Before your next board discussion on U.S. entry, work through these questions with your regulatory, clinical and market access leads in the same room.

  1. Does the device sit in a Medicare benefit category and would it be separately payable? If not, RAPID is closed to you and your access strategy runs through other channels, such as local coverage, hospital budgets or commercial payers.
  2. Is it a candidate for Breakthrough designation? FDA’s Breakthrough Devices Program requires more effective treatment or diagnosis of a life-threatening or irreversibly debilitating condition, plus at least one further criterion such as no approved alternative or a significant advantage over existing options. Requests go in as a Q-Submission, and FDA intends to decide within 60 calendar days.
  3. Which regulatory route applies? RAPID covers Class II devices in TAP heading for De Novo and Class III devices heading for PMA. A device expected to go through 510(k) is outside the proposal.
  4. Where is your IDE today? If you have not yet held an IDE pre-submission meeting, you are at the entry point. If you are past it, plan for the standard NCD process unless the final notice adds a transition.
  5. Can your pivotal study enroll enough Medicare beneficiaries at U.S. sites? This is often the most expensive answer, and the one that most changes a European or Asian company’s trial plan.
  6. Can you show substantial clinical improvement for inpatient or outpatient add-on payments? Unless you held Breakthrough designation by September 30, 2026, the payment shortcut is gone, and your evidence plan has to carry that burden too.

What this means if you are entering the U.S.

The 2026 changes reward companies that treat U.S. market access as a design input from the first protocol draft. If your device could qualify, the prize is real: a coverage decision in months instead of a year or more, and a clear signal to hospitals that Medicare will pay. The cost is front-loaded. You commit to U.S. clinical sites, Medicare-relevant endpoints and early conversations with two agencies before you have U.S. revenue.

For companies that do not fit RAPID, the message is just as practical. The route to national coverage still exists, but the inpatient and outpatient payment advantages that made Breakthrough designation so valuable are narrowing. A U.S. business case built in 2024 on those advantages deserves a fresh look now.

Either way, the final RAPID notice is the next date to watch. It will settle the questions CMS left open, including what happens to devices already under an IDE, and it starts the clock for everyone who qualifies.

Frequently asked questions

What is the CMS RAPID pathway?

RAPID (Regulatory Alignment for Predictable and Immediate Device) is a proposed CMS and FDA pathway for certain Breakthrough Devices. The two agencies agree on the evidence before the pivotal study, CMS issues a proposed national coverage determination on the day FDA authorizes the device, and CMS targets a final decision 60 days later for Class II devices and 90 days later for Class III devices.

Is RAPID in effect yet?

Not as of November 2026. The proposed notice was published on August 11, 2026, comments closed on October 13, 2026, and CMS has said the pathway takes effect when it publishes the final notice.

Can I still use TCET for Medicare coverage of a breakthrough device?

CMS has said TCET is paused for new candidates while it implements RAPID. The standard national coverage determination process remains available.

Do breakthrough devices still get NTAP automatically?

No. Starting with FY 2028 applications, CMS repealed the alternative pathway that exempted Breakthrough Devices from showing substantial clinical improvement. Devices designated by September 30, 2026 that receive FDA authorization by May 1, 2028 can still use the alternative pathway through FY 2029.

Let’s build the bridge together

Shanbridge helps healthcare and medtech companies turn U.S. market access into clear executive decisions, from evidence strategy and payer positioning to the partnerships that make a launch work. If you are weighing how these changes affect your U.S. plan, start the conversation.

References

This article is general information about U.S. regulatory and reimbursement developments as of November 2026. It is not legal, regulatory or reimbursement advice. Proposed policies may change before they are finalized; confirm current requirements with CMS, FDA and qualified advisors before making decisions.

Shani Madaminova
Shani Madaminova
https://shani.me
Shani Madaminova is the founder of Shine & Rise, a contemplative practice for modern adults. Her work integrates contemplative traditions, nervous-system science, and the practical realities of running a life inside contemporary professional environments.